TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Capsule Endoscopy in Patients With Suspected Crohn's Disease

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients ages 10-65 years, inclusive~  * Patient suffers from either~    * diarrhea for more than 6 weeks and less than 3 years and/or~   * abdominal pain for more than 6 weeks and less than 3 years and/or~   * extra-luminal manifestations of IBD including: erythema nodosum, pyoderma gangrenosum, arthritis, peri-anal disease, uveitis, aphthous stomatitis~ * Patient suffers from at least one of the symptoms / lab abnormalities listed below:~    * Positive inflammatory marker (ESR, CRP, thrombocytosis, leukocytosis, fecal lactoferrin, fecal alpha-1 antitrypsin) within 3 months prior to enrollment~   * Unexplained anemia (less than normal limits) within 3 months prior to enrollment~   * Hypoalbuminemia (\<3.5 g/dl) within 3 months of enrollment~   * Positive ASCA within 3 months of enrollment~   * Abnormal white blood cell scan with in 3 months of enrollment~   * Stool negative for O\&P (C\&S) within 3 months of enrollment~   * Recurrent Fevers~   * Unexplained weight loss, failure to thrive in children~   * Gastro-intestinal bleeding including melena and/or hematochezia and/or FOBT positive.~   * Chronic perianal disease (fistula, fissure, peri-rectal abscess)~   * Abnormal small bowel SBFT and/or enteroclysis and/or abdominal CT not conclusively diagnostic for IBD~ * Patient is indicated for Ileo-Colonoscopy~ * Patient or legal guardian agrees to sign consent form~Exclusion criteria:~* Indeterminate Colitis where the purpose is only to make a definitive diagnosis and where the inclusion criteria are not otherwise met~* Known intestinal obstruction or current obstructive symptoms, such as severe abdominal pain with accompanying nausea or vomiting.~* Definite long stricture seen on radiological exam.~* Suspected GI stricture, followed by agile™ study that could not prove patency of the GI tract.~* Known history of small bowel Crohn's Disease~* Current treatment for active IBD~* Positive Anti-tTG or anti-endomysial antibody~* Any of the following work-up within 1 year of study entry: Capsule Endoscopy, Colonoscopy and Upper GI/SBFT.~* Non-steroidal anti-inflammatory drugs including Aspirin, (twice weekly or more) during the 4 weeks preceding enrollment~* Patient is pregnant

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Using Interactive Virtual Presence to Remotely Assist Parents With Child Restraint Installations

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* own a vehicle and have a child who rides in that vehicle using a child restraint fastened with a harness.~Exclusion Criteria:~* not physically capable of installing a child restraint into a vehicle, which may exclude individuals with various disabilities.~* not able to communicate orally in English or Spanish, although significant demand for training in other languages may alter this exclusion criteria in the future

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Interactive virtual presence (Type: EXPERIMENTAL): Participants will engage remotely with a certified child restraint technician via interactive virtual presence. They will work together to help the participant install his or her child restraint properly into his or her vehicle. Standard Safe Kids Worldwide protocols will be followed, with the exception that the interaction will occur remotely via interactive virtual presence.
- Live technician (Type: ACTIVE_COMPARATOR): Participants will engage live with a certified child restraint technician. They will work together to help the participant install his or her child restraint properly into his or her vehicle. Standard Safe Kids Worldwide protocols will be followed.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Preservation of Beta-cell Function in Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* type 2 diabetes mellitus diagnosed within the prior 2 months~* HbA1c \> 7% at the time of inclusion~* willing to perform intensive diabetes management~* able to comply with treatment and follow-up regimen~Exclusion Criteria:~* HbA1c \> 8% at time of randomization~* creatinine \> 1.5 mg/dl~* liver function tests \> 3 times the upper limit of normal~* severe anemia~* severe proliferative retinopathy~* NYHA class III or IV heart failure~* active CAD or recent (within 6 months) MI~* pregnant, willing to get pregnant, or not willing to practice any contraceptive method~* non-english speaking~* active heavy alcohol or illicit drug users (within past 6 months)~* history of lactic acidosis

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Metfomin and Insulin (Type: ACTIVE_COMPARATOR): Metformin 1000mg/BID and Insulin Novolog 70/30 per protocol titration
- Metformin, Pioglitazone and Glyburide (Type: ACTIVE_COMPARATOR): Metformin 1000mg/BID, Pioglitazone 45 mg and glyburide per protocol titration

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF

Study Design Characteristics:
- Allocation: None
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Primary myelofibrosis, post-PV MF, or post-ET MF that requires therapy~* MF patients must have received prior JAK2 inhibitor therapy, and been found to be intolerant, or refractory/relapsed from prior JAK2 inhibitor therapy, based on investigator assessment~* ≥18 years old~* ECOG Performance Status of ≤ 3~* Estimated life expectancy of ≥12 weeks~* Male or non-pregnant, non-lactating female patients~* Serum creatinine of ≤1.5 × the upper limit of normal (ULN)OR estimated creatinine clearance (CrCl) ≥ 40 ml/min/1.73 m2~* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤3 × the upper limit of normal (ULN) and total bilirubin ≤1.5 × ULN. If the total bilirubin is elevated between 1.5 x and 3 x ULN, patients with a direct bilirubin ≤ 1.5 X ULN are eligible during the Phase II portion.~* Absolute neutrophil count (ANC) \>1000/μL and Platelet count \> 25,000/μL~* QTcB ≤ 480 msec~* No MF-directed treatment for at least 2 weeks prior to initiation of NS-018, including any use of corticosteroids for Myelofibrosis symptom or blood count management. Low dose corticosteroids ≤ 10 mg/day prednisone or equivalent is allowed for non-myelofibrosis purposes.~Exclusion Criteria:~* Active, uncontrolled systemic infection~* Patients with any unresolved toxicity greater than Grade 1 from previous anticancer therapy~* Potentially curative therapy is available~* Currently taking medication that is substantially metabolized by cytochrome P450 (CYP) 1A2 or CYP3A4 or taking medication known to be strong inhibitors or inducers of CYP3A4~* Patients with a serious cardiac condition within the past 6 months~* Pregnant or lactating~* Radiation therapy for splenomegaly within 6 months prior to study entry~* Splenectomy (Phase 2 portion of the study only)~* Known HIV positive status~* Known active hepatitis, a history of viral hepatitis B or hepatitis C

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention: Drug: NS-018 (Type: EXPERIMENTAL): In Phase 1 part, subjects were treated with oral NS-018 at a dose of 75 - 400 mg once daily or 100 - 400 mg twice daily. In Phase 2 part, subjects were treated with oral NS-018 at a dose of 300 mg once daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adult (according to local legislation) male or female patient~* Chronic hepatitis C (CHC)~* Patients naïve to CHC treatment or patients who received prior interferon-based therapy for CHC for whom data on treatment received and treatment outcome is available; information on fibrosis stage prior to previous treatment is also required~Exclusion Criteria:~* Co-infection with hepatitis B~* History or evidence of decompensated liver disease~* History of major organ transplantation with an existing functional graft (including liver transplantation)~* End stage renal disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Chronic hepatitis C patients (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Compound Edaravone Injection for Treatment of Acute Ischemic Stroke

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Hospitalized patients, diagnosed of ischemic stroke;~* Onset of stroke is less than or equal to 48 hours;~* There are clear signs of neurological deficit: 4≤NIHSS score≤24, and also, the sum of NIHSS score for the upper limb and the lower limb is greater than or equal to 2;~* Patients signed written inform consent~Exclusion Criteria:~* Cranial CT scan finds intracranial bleeding disorders: hemorrhagic stroke, epidural hematoma, intracranial hematoma, intraventricular hemorrhage, subarachnoid hemorrhage;~* Iatrogenic stroke;~* Severe disturbance of consciousness: NIHSS category 1a for consciousness is greater than 1；~* The mRS score prior to this onset is greater than 1;~* Transient ischemic attack (TIA);~* SBP after blood pressure control is still greater than or equal to 220 mmHg, or DBP after blood pressure control is still greater than or equal to 120 mmHg;~* Patients with severe mental disorders and dementia;~* ALT or AST is greater than 2.0×ULN or previously known liver diseases, such as acute hepatitis, chronic active hepatitis, liver cirrhosis;~* Serum Creatinine (SCr) is greater than 1.5×ULN, Creatinine Clearance (CrCl) is less than 50 ml/min or previously known severe renal diseases;~* Therapeutic neuroprotective agents have been applied after onset of stroke, including commercially available edaravone, nimodipine, ganglioside, citicoline, piracetam, butyl benzene peptides, Urinary Kallidinogenase;~* Arterial or venous thrombolytic therapy has been applied after onset of stroke;~* Patients with malignant tumors or receiving concurrent antitumor treatment;~* Patients with severe systemic disease, life expectancy is less than 90 days;~* allergic to edaravone , (+)-Borneol or related excipients;~* Pregnant or lactating women;~* Have major surgery within 4 weeks before enrollment;~* Participated in other clinical studies within 30 days before randomization; or participating in other clinical trials at present;~* The investigators consider the patients are not suitable for this trial.

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Compound Edaravone (Type: EXPERIMENTAL): Compound Edaravone Injection 37.5mg/dose (Edaravone 30mg, (+)-Borneol 7.5mg), one dose every 12 hours, continue for 14 days
- Edaravone (Type: ACTIVE_COMPARATOR): Edaravone Injection 30 mg/dose, one dose every 12 hours, continues for 14 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study on the Treatment of Elderly Patients With Older and Newer Antiepileptic Drugs

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age 60 yrs or above.~* New onset focal epilepsy i.e. either at least one epileptic seizure in the last 6 months and focal epileptiform discharges on EEG or a relevant lesion on CT/MRI or at least 2 epileptic seizures, one of which occurring in the last 6 months prior inclusion.~* No previous AED treatment, except for a period not longer than 4 weeks prior to inclusion (V0).~* Ability of subject to understand verbal and written instructions, to comply with all study requirements, and to comprehend character and individual consequences of the clinical trial.~* Written informed consent before enrolment in the trial.~Exclusion Criteria:~* Acute symptomatic epileptic seizures occurring acutely within a 2 week period after the onset of an acute illness such as cerebral haemorrhage, cerebral infarct, rapid progressive malignancy or other acute brain abnormalities (i.e. encephalitis, hypoxic brain damage, trauma, metabolic derangement, following brain surgery).~* Dementia (as defined by history)~* Renal insufficiency as defined by GFR \< 50 mL/min.~* Increased liver enzymes (GOT, GPT, gGT) or increased bilirubin ≥ 2-fold the upper limit of normal (ULN).~* Pre-treatment with valproic acid within the four weeks prior inclusion (V0).~* Contraindication against or history of hypersensitivity to any of the investigational medicinal products or to any drug with similar chemical structure or to any excipient present in the pharmaceutical form of the investigational medicinal products.~* Participation in other clinical trials and observation period of competing trials within the last 2 months, respectively.~* History of drug or alcohol abuse within the last 2 years.~* Medical condition which interferes with the participation in the trial according to the opinion of the investigator.~* Patients with life expectancy \< 1 year due to malignant disease~* Psychiatric morbidity requiring legal guardianship.

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Levetiracetam (Type: ACTIVE_COMPARATOR): Levetiracetam
- Carbamazepine (Type: ACTIVE_COMPARATOR): Carbamazepine
- Lamotrigine (Type: ACTIVE_COMPARATOR): Lamotrigine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Curcumin Addition to Antipsychotic Treatment in Chronic Schizophrenia Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-60 years, male or female~* DSM-IV criteria for schizophrenia.~* Ability and willingness to sign informed consent for participation in the study~* SANS (Scale of Negative Symptoms of Schizophrenia ) \> 30 points~* Fixed antipsychotic dosages at least 3 months~* Steady mental state of patients at least 3 months~Exclusion Criteria:~* Current substance use disorder except nicotine dependence~* Regular use of NSAID (non-steroidal anti-inflammatory drugs)~* Cancer history~* Untreated or severe hypertension~* Poorly controlled diabetes mellitus Type I or Type II~* Chronic liver \& gallbladder diseases~* Recent GERD (Gastroesophageal Reflux Disorder)~* Neurological disorders: epilepsy, stroke~* Hamilton Depression Scale Hamilton Depression Rating Scale (HAM-D-17 item) \> 24 points~* Patients with a known hypersensitivity to curcumin~* Pregnant women or a woman who intends to become pregnant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- curcumin (Type: ACTIVE_COMPARATOR): curcumin 3 g/day for 6 months
- placebo (Type: PLACEBO_COMPARATOR): curcumin 3 g/day for 6 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Early Phase 2 Clinical Study of TS-142 in Patients With Insomnia Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Outpatients~* Patients diagnosed with insomnia disorder according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5)~* Patients who scored 15 or higher on the Insomnia Severity Index (ISI) at Visit 1~* Other protocol defined inclusion criteria could apply~Exclusion Criteria:~* Patients with a history of any of the following diseases according to the DSM-5 criteria:~  1. Hypersomnolence disorder~ 2. Narcolepsy~ 3. Breathing-related sleep disorders~ 4. Circadian rhythm sleep-wake disorder~ 5. Parasomnias~ 6. Restless legs syndrome~ 7. Substance/medication-induced sleep disorder~* Patients complicated with organic brain disease (including neurodegenerative disease, cerebrovascular disorder), and/or epilepsy~* Patients with a history of poorly controlled diabetes mellitus (HbA1c \>8%)~* Patients with difficulty in sleeping due to medical problems such as pain, pruritus, heart disease, nocturia (\>3 times per night), bronchial asthma, reflux oesophagitis, endocrine disease, hot flush, and periodic limb movement disorder~* Other protocol defined exclusion criteria could apply

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- 5 mg (Type: EXPERIMENTAL): Period in which participants received single-dose of 5 mg TS-142 prior to bedtime
- 10 mg (Type: EXPERIMENTAL): Period in which participants received single-dose of 10 mg TS-142 prior to bedtime
- 30 mg (Type: EXPERIMENTAL): Period in which participants received single-dose of 30 mg TS-142 prior to bedtime
- Placebo (Type: PLACEBO_COMPARATOR): Period in which participants received single placebo prior to bedtime

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evolving Treatment Modalities for Management of Patients Suffering From Disc Displacement With Reduction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* TMJ with audible and palpable click.~* Patients with anterior disc displacement as detected by MRI.~* Presence of full or nearly full complement of natural teeth.~Exclusion Criteria:~* Patients who have radiographic evidence of degenerative conditions of TMJ.~* Patients who have anterior disc dislocation without reduction.~* Previous history of TMD treatment.~* History of recent trauma.~* The presence of systemic diseases (i.e. rheumatoid arthritis, osteoarthritis).~* Inability or unwillingness to undergo magnetic resonance imaging (MRI) such as implanted electronic devices.~* Pregnant and lactating females.~* Patients with known allergy to botulinum toxin type A.~* Patients suffering from neurological disorders.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Low level laser therapy (Type: EXPERIMENTAL): None
- Botulinum toxin type A (Type: EXPERIMENTAL): None
- Anterior repositioning appliance (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Efficacy of Suprainguinal Fascia Iliaca Compartment Block for Analgesia After Elective Total Hip Replacement.

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* age 18-75 years old~* informed consent to participate in the study~* ASA score I-III~* BMI -19-30kg/m2~* qualified for total hip replacement~* no contraindication to used anesthesia and drugs~Exclusion Criteria:~* contraindications to spinal anesthesia and regional blocks~* previously coexisting chronic pain~* previously opioids intake~* BMI\>30kg/m2~* allergy to drugs using during study~* mental status preventing the usage of patient controlled analgesia pump

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Opioid and non opioid postoperative analgesia. (Type: PLACEBO_COMPARATOR): Group of patients with opioid and non opioid based postoperative analgesia without preoperative regional anaesthesia and dexamethasone.
- Regional anaesthesia, opioid and non opioid postoperative analgesia. (Type: EXPERIMENTAL): Group of patients with opioid and non opioid based postoperative analgesia with preoperative regional anaesthesia and without preoperative dexamethasone.
- Regional anaesthesia, dexamethasone, opioid and non opioid postoperative analgesia (Type: EXPERIMENTAL): Group of patients with opioid and non opioid based postoperative analgesia with preoperative regional anaesthesia and dexamethasone.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete